Drug Trial Radar · NCT00314704
Dopamine and Norepinephrine in Shock Patients
Last checked: Nov 20, 2026Latest source record: Feb 1, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,679
Actual
Start
Dec 2003
Primary completion
Oct 2007
Study completion Oct 2007
Sponsor
- Lead sponsor
- Sepsis Occurrence in Acutely Ill PatientsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of dopamine and norepinephrine, two commonly used vasopressor agents, in the treatment of shock.
Conditions
- Shock
Interventions
dopamine versus norepinephrineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28 day survival
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
University Hospital of Vienna
Vienna, Austria
CHU Saint Pierre
Brussels, Belgium
CHU Brugmann
Brussels, Belgium
HIS Ixelles
Brussels, Belgium
Erasme University Hospital
Brussels, Belgium
St Elisabeth
Brussels, Belgium
CHU Charleroi
Charleroi, Belgium
Hospital Universitario Rio Hortega
Valladolid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.